Biz: Glaxo’s diabetes drug Avandia proving to be a huge headache
- 1.5% the share of Glaxo’s revenues the diabetes drug accounted for in 2009
- 39% the average percentage that Avandia increased the risk of heart attacks in numerous studies
- $460M the amount Glaxo agreed to pay to settle thousands of annoying lawsuits source
- » And it could get worse: Today, a group of Food and Drug Administration advisers will suggest whether or not the drug should go off the market. If it’s banned, expect the massive drug company to be on the hook for even more lawsuits.